Allergan CEO Gets $15.7 Million Bonus if He Says Yes to GSK
Allergan CEO David Pyott could get a $15.7 million change-of-control bonus if he says yes to GlaxoSmithKline’s alleged interest in buying his company.
The potential windfall is detailed in Allergan’s proxy statement filed with the SEC. Pyott gets $2.3 million if the company has a change in control (i.e. GSK buys all its shares). But he gets $15.7 million if his job is terminated after a change in control. (The proxy covers 2008; the deal in 2009 may have changed, but this is the most recent information available.)
The bonus includes vesting of stock and options, continued benefits, and cash.
If the top five execs left the company post-acquisition, they could walk away with a total of $37 million in extra compensation between them. Here’s the breakdown of awards for change in control followed by termination:
- Name, change of control followed by termination pay
- CEO David Pyott, $15,742,387
- CFO Jeffrey Edwards, $4,057,483
- President F. Michael Ball, $5,693,451
- General Counsel Douglas Ingram, $5,827,388
- EVP/R&D Scott Whitcup, $5,617,839
- Source: SEC.
As you can see by the sudden and sustained rise in Allergan’s stock price (pictured), the market still believes something is going on between these two sets of companies … Stay tuned.
- See BNET’s previous coverage:
- The GlaxoSmithKline-Allergan Deal Worst-Case Scenario
- Allergan CEO Pyott Received Pay Raise to $11.9 Million
Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.
BNET User Analysis